Thank you for Subscribing to Life Science Review Weekly Brief
Conclusively, Sallman said that they have several mutations that they can already According to a speaker at Chemotherapy Foundation Symposium, patients with myelodysplastic syndrome will need to be incorporated of next-generation sequencing into the standard of practice which will impact all facets of care
According to a speaker at Chemotherapy Foundation Symposium, patients with myelodysplastic syndrome will need to be incorporated of next-generation sequencing into the standard of practice which will impact all facets of care. David A. Sallman, MD, assistant member of the department of malignant hematology at Moffitt Cancer Center, during his presentation stated that the costs need to be considered and the reduction of turnaround is important. He added that currently, clinical prognostic systems are lower vs. higher risk, but the incorporation of mutations can really help significantly stratify outcomes based on the underlying mutations. These will not only predict outcomes but will piece out very important groups.
Incorporation of mutation presence to help diagnose myelodysplastic syndrome with ringed sideroblasts has already been impacted by next-generation sequencing on the diagnosis.
According to the revised International Prognostic Scoring System, researchers have used factors such as age, peripheral blood blasts, and red blood cell transfusion dependence to further risk-stratify patients deemed an intermediate risk. However, an optimal molecular model will be used to personalize the prognosis of patients at diagnosis and sequentially over time says Sallman. While the turnaround time continues to improve, clinicians can wait for the results of sequencing panels for the vast majority of patients with myelodysplastic syndrome. Other factors that can provide a high pretest probability of whether a patient may have a mutation include therapy-related history, refractory anemia, multiple abnormalities, excess blasts with increased ringed sideroblasts, target, P53, which he hopes to have shown to really require clinical trials if at all possible, but there are other mutations.